FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	DC	20549	
vasiliigion,	D.C.	20349	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average	burden									
hours per response	: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LEE KENNETH B JR</u>				BIG	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX]							[(Ch	elationship eck all appli Directo	cable) or	g Per	10% Ov	vner		
(Last) 4505 EM	,	irst) LVD., SUITE 20	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/13/2023							below)	(give title		Other (s below)	specify		
				4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) DURHA	M N	C	27703		_											iled by Mor		orting Person One Repo	
(City)	(S	tate)	Ru	Rule 10b5-1(c) Transaction Indication															
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,		3. Transaction Code (Instr. b) 8) 4. Securities Acc Disposed Of (D) 5)		ities Acq d Of (D) (uired (Instr.	(A) or 3, 4 and	Benefici Owned I	es Fo ially (D) Following (I)		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	unt (A) (D)		Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)	
Common Stock 06/13/2				3/2023	1023 A 16,74		5 ⁽¹⁾ A \$		\$0	68,863			D						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year)				ransaction of code (Instr.) Se Ac (A Di of (Instr.)		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	OI Ni Of	umber					
Automatic Stock Option Grant ⁽²⁾	\$8.18	06/13/2023			A		39,072		06/13/2024	4 0	6/13/2033	Commo Stock		9,072	\$0	39,072	2	D	

Explanation of Responses:

- 1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
- $2. \ Automatic \ non-employee \ director \ grant \ of \ stock \ options \ pursuant \ to \ the \ Director \ Compensation \ Policy.$

/s/ Alane P. Barnes, by power of attorney

06/15/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.